The European Commission has authorized the commercialization of the combination of dapagliflozine and metformin hydrochloride, a drug that Astrazeneca markets under the name of 'Xigduo', as a treatment of type 2 diabetes in patients over 18 years, as a complement to the diet andExercise to improve glycemic control in patients not properly controlled with the maximum tolerated dose of monotherapy metformin.
The drug is presented in two doses, 5 thousandigrams per 850 and 1,000 milligrams, and is the first administrative approval for a fixed metformin dose combination and an SGLT2 inhibitor, two antihyperglucemic products with complementary action mechanisms that allow improving the controlGlucémica in a tablet administered twice a day.
The SGLT2 are sodium-glucose cotransporters that are mainly in the kidney and are responsible for the majority of glucose reabsorption.
In patients with type 2 diabetes, the kidney capacity to reabsorb glucose is approximately 20 percent greater, exacerbating hyperglycemia associated with the disease, hence its selective inhibition reduces the reabsorption of excess glucose and allows its eliminationThrough urine.
The authorization of the EU will also allow its use in combination with other hypoglycemic medications, such as insulin, in patients not properly controlled with metformin and other medications, and in patients who are already being treated with the combination of Dapagliflozine and metformin in separate tablets.
"This new drug is an important incorporation to medications that help patients handle glycemic control," according to Elisabeth Björk, vice president and development director of the cardiovascular and metabolic area of the last phase of Astrazeneca.
(EuropePress)
